---
title: "McKesson Corporation: Business Model"
description: "McKesson Corporation revenue by business segment from its fiscal 2026 Form 10-K, with each part's share, growth and profitability explained."
canonical: https://www.getswoopr.com/stocks/companies/mckesson-corporation/business-model/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# McKesson Corporation: Business Model & Revenue Engine

## Direct Answer

McKesson Corporation reports revenue across 4 business segments in its fiscal 2026 Form 10-K. North American Pharmaceutical is the largest, with $337 billion of revenue (83% of the total), followed by Oncology and Multispecialty at $48.4 billion (12%).

## How Does McKesson Corporation Make Money?

North American Pharmaceutical supplies 83% of revenue, so McKesson Corporation's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2025 and 2026, Oncology and Multispecialty grew fastest (+31.4%) and Medical Surgical Solutions slowest (+1.1%), so the revenue mix tilts toward Oncology and Multispecialty while that gap lasts.

| Segment | FY2026 revenue | FY2025 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| North American Pharmaceutical | $337 billion | $305 billion | 83.4% | 10.6% |
| Oncology and Multispecialty | $48.4 billion | $36.9 billion | 12.0% | 31.4% |
| Medical Surgical Solutions | $11.5 billion | $11.4 billion | 2.9% | 1.1% |
| Prescription Technology Solutions | $5.8 billion | $5.2 billion | 1.4% | 11.3% |

![Bar chart of McKesson Corporation revenue by segment for fiscal 2026: North American Pharmaceutical 83.4%, Oncology and Multispecialty 12.0%, Medical Surgical Solutions 2.9%, Prescription Technology Solutions 1.4%.](https://www.getswoopr.com/images/charts/mckesson-corporation-business-model-segment-mix.webp)
*McKesson Corporation revenue by segment as a share of total revenue, from the table above. The largest is highlighted. Select the chart to open it full size.*

## What the Segment Figures Do Not Show

The rows above add up to 100% of McKesson Corporation's reported revenue for fiscal 2026; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.

## Where These Numbers Come From

Every figure on this page is a value McKesson Corporation reported in the segment note and revenue disclosures of its Form 10-K filed May 8, 2026 (accession 0000927653-26-000069), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.

Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2026; it is not a forecast or a recommendation.

## Frequently Asked Questions

### What are McKesson Corporation's business segments?

In its fiscal 2026 Form 10-K, McKesson Corporation reports revenue for North American Pharmaceutical, Oncology and Multispecialty, Medical Surgical Solutions and Prescription Technology Solutions.

### Which part of McKesson Corporation brings in the most revenue?

North American Pharmaceutical, with $337 billion of revenue in fiscal 2026, or 83% of the total.

### Where does McKesson Corporation report its segment results?

In the segment note to the financial statements in its Form 10-K, most recently filed May 8, 2026, alongside management's discussion of each segment's results.

## References

- [SEC EDGAR: MCKESSON CORP Form 10-K filed May 8, 2026](https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm)
- [SEC EDGAR: MCKESSON CORP annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=927653&type=10-K)
- [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces)
- [SEC: Financial Statement Data Sets](https://www.sec.gov/data-research/sec-markets-data/financial-statement-data-sets)

## Related Pages

- [McKesson Corporation company dossier](https://www.getswoopr.com/stocks/companies/mckesson-corporation/)
- [McKesson Corporation financial metrics](https://www.getswoopr.com/stocks/companies/mckesson-corporation/metrics/)
- [McKesson Corporation financial risk indicators](https://www.getswoopr.com/stocks/companies/mckesson-corporation/risks/)
- [McKesson Corporation peer comparison](https://www.getswoopr.com/stocks/companies/mckesson-corporation/competitors/)
- [McKesson Corporation business model and revenue mix](https://www.getswoopr.com/stocks/companies/mckesson-corporation/business-model/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).